Shares of Advanced Cell Technology Inc. (OTC: ACTC), a biotechnology company engaged in the development and commercialization of human embryonic and adult stem cell technology, are continuing to rally in trading today.
At last check, ACTC shares were trading 20.89% higher at $0.0816 on above average volume of 8.08 million. The stock has now gained more than 26% in the last three trading sessions.
Advanced Cell shares are gaining after the company this week secured approval to proceed with increased retinal pigment epithelial (RPE) dosage for patients in clinical trial for dry age-related macular degeneration (dry AMD).
ACTC received the authorization from the independent Data and Safety Monitoring Board (DSMB). The DSMB comprises of medical experts, who are closely monitoring ACTC’s three ongoing trials.
Advanced Cell Technology Chairman and CEO Gary Rabin said that the DSMB authorization to move to the higher dosage represents a significant milestone for ACTC’s clinical programs.
Recent Comments